223 related articles for article (PubMed ID: 34271165)
21. Glioblastoma as a Novel Drug Repositioning Target: Updated State.
Hosseinalizadeh H; Ebrahimi A; Tavakoli A; Monavari SH
Anticancer Agents Med Chem; 2023; 23(11):1253-1264. PubMed ID: 36733195
[TBL] [Abstract][Full Text] [Related]
22. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
[TBL] [Abstract][Full Text] [Related]
23. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: The promise of nanomedicine.
Kim SS; Harford JB; Pirollo KF; Chang EH
Biochem Biophys Res Commun; 2015 Dec; 468(3):485-9. PubMed ID: 26116770
[TBL] [Abstract][Full Text] [Related]
24. Biocompatible copolymer formulations to treat glioblastoma multiforme.
Erthal LCS; Gobbo OL; Ruiz-Hernandez E
Acta Biomater; 2021 Feb; 121():89-102. PubMed ID: 33227487
[TBL] [Abstract][Full Text] [Related]
25. Glioblastoma: Current Status, Emerging Targets, and Recent Advances.
Thakur A; Faujdar C; Sharma R; Sharma S; Malik B; Nepali K; Liou JP
J Med Chem; 2022 Jul; 65(13):8596-8685. PubMed ID: 35786935
[TBL] [Abstract][Full Text] [Related]
26. Distinct cellular responses induced by saporin and a transferrin-saporin conjugate in two different human glioblastoma cell lines.
Cimini A; Mei S; Benedetti E; Laurenti G; Koutris I; Cinque B; Cifone MG; Galzio R; Pitari G; Di Leandro L; Giansanti F; Lombardi A; Fabbrini MS; Ippoliti R
J Cell Physiol; 2012 Mar; 227(3):939-51. PubMed ID: 21503892
[TBL] [Abstract][Full Text] [Related]
27. C1q/TNF-related peptide 8 (CTRP8) promotes temozolomide resistance in human glioblastoma.
Thanasupawat T; Glogowska A; Burg M; Krcek J; Beiko J; Pitz M; Zhang GJ; Hombach-Klonisch S; Klonisch T
Mol Oncol; 2018 Sep; 12(9):1464-1479. PubMed ID: 29949238
[TBL] [Abstract][Full Text] [Related]
28. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
Reddy RG; Bhat UA; Chakravarty S; Kumar A
Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
[TBL] [Abstract][Full Text] [Related]
29. Comparative expression study of the endo-G protein coupled receptor (GPCR) repertoire in human glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targets.
Fève M; Saliou JM; Zeniou M; Lennon S; Carapito C; Dong J; Van Dorsselaer A; Junier MP; Chneiweiss H; Cianférani S; Haiech J; Kilhoffer MC
PLoS One; 2014; 9(3):e91519. PubMed ID: 24662753
[TBL] [Abstract][Full Text] [Related]
30. Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Custodio A; Calles A; Pérez-Segura P
Clin Transl Oncol; 2010 Apr; 12(4):310-4. PubMed ID: 20462843
[TBL] [Abstract][Full Text] [Related]
31. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
32. Current State of Immunotherapy for Treatment of Glioblastoma.
McGranahan T; Therkelsen KE; Ahmad S; Nagpal S
Curr Treat Options Oncol; 2019 Feb; 20(3):24. PubMed ID: 30790064
[TBL] [Abstract][Full Text] [Related]
33. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme.
White E; Bienemann A; Taylor H; Hopkins K; Cameron A; Gill S
Contemp Clin Trials; 2012 Mar; 33(2):320-31. PubMed ID: 22101221
[TBL] [Abstract][Full Text] [Related]
35. Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness.
Varricchio A; Ramesh SA; Yool AJ
Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769339
[TBL] [Abstract][Full Text] [Related]
36. Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection.
Graham-Gurysh E; Moore KM; Satterlee AB; Sheets KT; Lin FC; Bachelder EM; Miller CR; Hingtgen SD; Ainslie KM
Mol Pharm; 2018 Mar; 15(3):1309-1318. PubMed ID: 29342360
[TBL] [Abstract][Full Text] [Related]
37. Eph receptors as therapeutic targets in glioblastoma.
Day BW; Stringer BW; Boyd AW
Br J Cancer; 2014 Sep; 111(7):1255-61. PubMed ID: 25144626
[TBL] [Abstract][Full Text] [Related]
38. Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets.
Mao H; Lebrun DG; Yang J; Zhu VF; Li M
Cancer Invest; 2012 Jan; 30(1):48-56. PubMed ID: 22236189
[TBL] [Abstract][Full Text] [Related]
39. Novel delivery strategies for glioblastoma.
Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
[TBL] [Abstract][Full Text] [Related]
40. Recent Advances in the Use of Lipid-Based Nanoparticles Against Glioblastoma Multiforme.
Ortega-Berlanga B; Gonzalez C; Navarro-Tovar G
Arch Immunol Ther Exp (Warsz); 2021 Mar; 69(1):8. PubMed ID: 33772646
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
